Navigation Links
Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
Date:9/9/2007

HILTON HEAD ISLAND, S.C., Sept. 9 /PRNewswire/ -- At approximately 3:21 PM today, Dr. Roger Kenneth Hershline PhD MD, Chairman and Founder of CureHIV.us, agreed to act as a conduit to provide samples of Global Humanceuticals, Inc's., new extremely effective, safe and stable drug candidate to profit, non-profit, academic, government, non-government, U.S. and foreign institutions, organizations, and corporations, under mutual agreements, contracts or partnerships, to spur theoretical, objective, mechanistic, developmental or clinical research. This unique new chemical entity is referred to as compound NIAID #11039. However, this invention has already received a patent called: Antiviral Composition, U.S. patent number: 6,821,958 on November 23, 2004. The World International Patent Organization published the International Application Number as PCT/US2005/039528 on November 5, 2006.

"This gift is intended to extend technology that no one else posses on this planet." Stated Dr. Hershline. "Already, Chinese scientists are very interested." Dr. Hershline hosted Session V at the World Aids Day Conference China Dec 1 to Dec 3, 2006, to initially present data an NIAID #11039. There was, unfortunately, a communication error from the National Institute of Health (NIH of the United States) to Dr. Hershline, which prevented presentation of test results.

The compound has a non-toxic alpha-glucose backbone, obtained from an abundant natural source. The backbone is chemically bi-substituted in a random fashion, by a new reaction. "The substitution groups are different sulfur based viral de-activating groups that work together to provide viral entry inhibition at concentrations of one pico-Molar. This active concentration is equivalent to diluting a 1% solution one million times.

The random substitutions are intended to prevent the virus from escaping de-activation thru mutation. "Global Humanceuticals, Inc.'s NIAID #11039 is the first drug designed to prevent the development of resistance, the biggest nightmare in HIV treatment," stated Dr. Hershline.

"I think we have to talk in terms of a cure for HIV. I want to cure HIV and that is why my foundation is called CureHIV.us," concluded Dr. Hershline.

Interested parties can contact Dr. Roger Kenneth Hershline PhD MD thru CureHIV.us Headquarters by email: Roger@CureHIV.us, mail P.O. Box 23467, Hilton Head Is., SC, 29925, by fax: 843-342-5924, phone: 843-342-5900. Direct to Dr. Hershline: 843-683-3683.


'/>"/>
SOURCE Global Humanceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/28/2020)... ... January 28, 2020 , ... Once a year at the International Association of ... innovative research and professional experiences, unmatched as a group together in one place at ... slated for March 26 – 29, is no different. Seven world-class speakers will ...
(Date:1/27/2020)... , ... January 27, 2020 , ... Today, The Beryl ... to elevate understanding of and track the current perspectives on patient experience in healthcare ... largely positive about their own experiences with the healthcare system but had a less ...
(Date:1/24/2020)... (PRWEB) , ... January 24, 2020 , ... ... resilience solutions, announces z/Archive, a new low-cost object storage solution using Transparent Cloud ... simple and inexpensive way to move older data to cloud storage, freeing up ...
Breaking Medicine Technology:
(Date:1/27/2020)... ... January 27, 2020 , ... Controlled Contamination Services is ... the East/Central Regions. As Vice President of the East/Central Regions, she will be responsible ... has been with CCS since 2015 and has been an integral part of the ...
(Date:1/27/2020)... ... 2020 , ... ResMed Launches AirFit F30i, Its First Tube-up Full Face CPAP ... launch of the AirFit F30i, Its First Tube-up Full Face ResMed CPAP Mask. The ... tube-down connection, compact under-the-nose or traditional over-the-nose cushion styles, and even memory foam versus ...
(Date:1/24/2020)... ... January 24, 2020 , ... A new study ... Bellefonte Hospital (OLBH) achieved a 59 percent decrease in hospital onset CDI. This ... Disease Control and Prevention. , The retrospective pre-post [study recently published ...
(Date:1/24/2020)... (PRWEB) , ... January 24, 2020 , ... ... teaming up with celebrity fitness expert and best-selling nutrition author Jorge Cruise to ... and intermittent fasting. , “I’m an enthusiastic advocate of intermittent fasting, that is ...
(Date:1/23/2020)... ... January 23, 2020 , ... A January 7 article ... rid of them. The article quotes the president of the American Society of Plastic ... They can be caused by a person’s facial structure including an undefined jawline, a ...
Breaking Medicine News(10 mins):